Abstract
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.
Keywords: Angiogenesis, antiangiogenesis, bortezomib, lenalinomide, multiple myeloma, thalidomide, thyrosine kinase inhibitors, zoledronic acid, chorioallantoic membrane, Monoclonal gammopathy of undetermined significance, Platelet-derived growth factor receptor, Hypoxia inducible factor 1 alpha, chorioallantoic membrane.
Current Cancer Drug Targets
Title:Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Volume: 12 Issue: 7
Author(s): Domenico Ribatti, Giuseppe Mangialardi and Angelo Vacca
Affiliation:
Keywords: Angiogenesis, antiangiogenesis, bortezomib, lenalinomide, multiple myeloma, thalidomide, thyrosine kinase inhibitors, zoledronic acid, chorioallantoic membrane, Monoclonal gammopathy of undetermined significance, Platelet-derived growth factor receptor, Hypoxia inducible factor 1 alpha, chorioallantoic membrane.
Abstract: Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.
Export Options
About this article
Cite this article as:
Ribatti Domenico, Mangialardi Giuseppe and Vacca Angelo, Antiangiogenic Therapeutic Approaches in Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429346
DOI https://dx.doi.org/10.2174/156800912802429346 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Significance of Various Experimental Models and Assay Techniques in Cancer Diagnosis
Mini-Reviews in Medicinal Chemistry Tetrapyrrolic Macrocycles: Potentialities in Medical Imaging Technologies
Current Organic Synthesis Anti-Shock Garments for Obstetric Hemorrhage
Current Women`s Health Reviews Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Size-tuneable Nanometric MRI Contrast Agents for the Imaging of Molecular Weight Dependent Transport Processes
Pharmaceutical Nanotechnology Oxidative stress and myocarditis
Current Pharmaceutical Design Synergistic Approaches to Clinical Oncology Biomarker Discovery
Current Topics in Medicinal Chemistry Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma
Current Pharmacogenomics and Personalized Medicine